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Abstract—Objective: The Quality Standards Subcommittee of the American Academy of Neurology and the Practice
Committee of the Child Neurology Society develop practice parameters as strategies for patient management based on
analysis of evidence. For this parameter the authors reviewed available evidence on the assessment of a child suspected of
having cerebral palsy (CP), a nonprogressive disorder of posture or movement due to a lesion of the developing brain.
Methods: Relevant literature was reviewed, abstracted, and classified. Recommendations were based on a four-tiered
scheme of evidence classification. Results: CP is a common problem, occurring in about 2 to 2.5 per 1,000 live births. In
order to establish that a brain abnormality exists in children with CP that may, in turn, suggest an etiology and prognosis,
neuroimaging is recommended with MRI preferred to CT (Level A). Metabolic and genetic studies should not be routinely
obtained in the evaluation of the child with CP (Level B). If the clinical history or findings on neuroimaging do not
determine a specific structural abnormality or if there are additional and atypical features in the history or clinical
examination, metabolic and genetic testing should be considered (Level C). Detection of a brain malformation in a child
with CP warrants consideration of an underlying genetic or metabolic etiology. Because the incidence of cerebral infarction
is high in children with hemiplegic CP, diagnostic testing for coagulation disorders should be considered (Level B).
However, there is insufficient evidence at present to be precise as to what studies should be ordered. An EEG is not
recommended unless there are features suggestive of epilepsy or a specific epileptic syndrome (Level A). Because children
with CP may have associated deficits of mental retardation, ophthalmologic and hearing impairments, speech and
language disorders, and oral-motor dysfunction, screening for these conditions should be part of the initial assessment
(Level A). Conclusions: Neuroimaging results in children with CP are commonly abnormal and may help determine the
etiology. Screening for associated conditions is warranted as part of the initial evaluation.
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Cerebral palsy (CP) can be defined as a disorder of
aberrant control of movement and posture, appearing
early in life secondary to a CNS lesion or dysfunction
that is not the result of a recognized progressive or
degenerative brain disease.1 The brain abnormality
may occur pre-, peri-, or postnatally. The diagnosis of
CP always involves a motor deficit and the usual pre-
senting complaint for which medical evaluation is
sought is that the child is not reaching motor mile-
stones at the appropriate chronological age. In most
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instances, a medical history establishes that the child
is not losing function, assuring that the patient does
not have a progressive disease. This history, combined
with a neurologic examination establishing that the
patient’s motor deficit is due to a cerebral abnormality,
leads to the diagnosis of CP. Serial examinations may
be necessary to assure the diagnosis of CP, especially
when the history is not reliable.
There is agreement that CP is due to a defect or
lesion in the developing brain, which may have had
its onset in the prenatal, perinatal, or postnatal peri-
od.1 While often a cutoff age for the appearance of
symptoms early in life is generally not given, the
great majority of children with CP present with
symptoms as infants or toddlers, and the diagnosis of
CP is made before age 2 years. In some children,
symptom onset may be delayed (e.g., dystonic cere-
bral palsy), whereas in other children the appear-
ance of pseudoprogression of symptoms may occur.
The term CP is descriptive and includes a number of
etiologies and clinical presentations. Although there
is no consensus about a precise age cut-off either for
the timing of the insult or the onset of symptoms, of
importance is that affected individuals have similar
needs for rehabilitation, education, and medical and
social services.
CP is a common problem. The worldwide incidence
of CP is approximately 2 to 2.5 per 1,000 live births.2
Each year about 10,000 babies born in the United
States develop CP.3 CP occurs more commonly in
children who are born very prematurely or at term.
Data from Sweden on 241 children with CP indicate
that 36% were born at a gestational age (GA) of less
than 28 weeks; 25% at 28 to 32 weeks GA; 2.5% at 32
to 38 weeks GA; and 37% at term.2
The types and severity of CP are clinically well
established. A Scandinavian study reported that 33%
of the CP population was hemiplegic, 44% diplegic,
and 6% quadriplegic.2
Half of the individuals with CP use assistive de-
vices such as braces, walkers, or wheelchairs to help
develop or maintain mobility and almost 70% have
other disabilities, primarily mental retardation.3 In-
dividuals with CP may need specialized medical
care, educational and social services, and other help
throughout their lives from their families and com-
munities. A study 10 years ago in California of the
extra economic costs associated with CP and 17
other congenital disorders (e.g., Down syndrome,
spina bifida) showed that CP had the highest life-
time costs per new case, averaging $503,000 in 1992
dollars.4
Laboratory tests are not necessary to confirm the
diagnosis of CP as it is based on the history and
examination. It is a syndrome with many etiologies.
Genetic diseases, brain malformations, infections,
and anoxic injury to the developing brain are a few of
the many causes of CP. Accurate determination of
the etiology of CP has specific implications regarding
treatment, prognosis, and ongoing medical manage-
ment of associated conditions. The importance of de-
termining whether there is a malformation, genetic
etiology, or injury and whether the injury is due to
an acquired pre-, peri-, or postnatal process has obvi-
ous significance from the point of view of assessment
of recurrence risk, counseling of families, and imple-
mentation of prevention programs, and when medi-
colegal issues arise. Determining causality also helps
limit further unnecessary testing. Finally, under-
standing the etiology of CP has implications for pre-
vention and intervention strategies. This knowledge
will direct further research efforts.
Determining the types of evaluations appropriate
for children with CP has posed tremendous chal-
lenges for parents and health care providers. The
purpose of this practice parameter is to review data
regarding the value and role of diagnostic tests used
to evaluate children diagnosed with CP. Data re-
garding the role of neuroimaging, metabolic and ge-
netic testing, and evaluation for coagulopathy are
discussed. There was insufficient evidence to make
any recommendations regarding the role of SPECT
scans or evoked potentials in children with CP. This
parameter also reviews evidence regarding the prev-
alence of associated problems such as epilepsy, men-
tal retardation, speech and language disorders, and
ophthalmologic and hearing impairments, and the
need for their systematic evaluation.
Description of process. Literature searches were
conducted with the assistance of the University of
Minnesota Biomedical Information Services for rele-
vant articles published from 1980 to March 2002.
Medline, CINAHL, and Healthstar databases were
searched for relevant articles published from 1966 to
2002, in the English language, using the following
key words: CP, magnetic resonance imaging, MRI,
computed axial tomography, CT scan, single photon
emission tomography, SPECT, metabolic disease,
thrombophilia, brain stem evoked potentials, sensory
evoked potentials, visual evoked potentials, electro-
encephalography (EEG), seizures, epilepsy, vision
loss, hearing loss, developmental delay, and speech
and language delay. Approximately 350 titles and
abstracts were reviewed for content regarding the
establishment of the etiology of CP. Articles were
excluded if the tests were ordered for reasons other
than to establish the etiology. We included only stud-
ies that contained more than 20 patients; smaller
case series were excluded. The ages of infants and
children included in these studies were similar to the
ages of children typically seen for diagnostic evalua-
tion so it was believed that the evidence-based rec-
ommendations included in this parameter were
appropriate. It was also believed that as CP is usually
due to a static process, it was unlikely for neuroimag-
ing studies to change over time so that data from stud-
ies done in older children with CP were valid regarding
etiologic yield. Each article was reviewed, abstracted,
and classified by a committee member. Data extracted
include first author, year, study population, study de-
sign, number of patients, types of CP, results of testing,
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and outcomes measured. A new four-tiered classifica-
tion scheme for determining the yield of established
diagnostic and screening tests developed by the Qual-
ity Standards Subcommittee was utilized as part of
this assessment (table 1). This classification scheme is
different from the one currently used in recently pub-
lished practice parameters that evaluate diagnostic,
prognostic, or therapeutic articles. Depending on the
strength of this evidence, it was decided whether spe-
cific recommendations could be made, and if so, the
level of strength of these recommendations (table 2).
Neuroimaging. Should neuroimaging be routinely
obtained in the child with CP?
Evidence. In neonates, neuroimaging is fre-
quently obtained when there is a history of complica-
tions during pregnancy, labor, and delivery; when
the infant is born very prematurely (32 weeks); or
when neurologic symptoms or findings are present
on neonatal examination. A practice parameter re-
garding the value of and indications for obtaining
neuroimaging in preterm and term infants has re-
cently been published.5 The current parameter ad-
dresses the role of neuroimaging in the infant or
child who has been diagnosed with or is suspected of
having CP based upon a motor deficit or delay that is
not worsening and a history and neurologic examina-
tion that places the lesion in the CNS. In some situ-
ations, the risks of obtaining a neuroimaging study
in an infant with CP may potentially outweigh the
benefits of further defining the etiology.
Recent data encompassing a total of 1,426 chil-
dren who underwent either CT6-14 or MRI15-24 scans
indicated an abnormality in 62% to 100% of individ-
uals (mean for CT, 77%; for MRI, 89%) (tables 3a and
4a). For the combined CT and MRI class I studies
(n  238), 88% of children had abnormal scans
whereas 77% of patients in a class II study (n  22)
had abnormal scans as did 83% of children in the
class III studies (n  1166). The timing of the brain
insult causing CP may be categorized into prenatal,
perinatal, and postnatal subgroups and the neuro-
pathologic changes seen in CP have been linked to
the gestational age of the infant at the time of insult.
Historical features (e.g., neonatal intracranial hem-
orrhage, neonatal encephalopathy, stroke, CNS in-
fection, trauma) or prior neuroimaging studies that
document such disorders or the presence of a brain
malformation may provide sufficient information to
establish the etiology when a child is seen later in
life as the symptoms of CP evolve. Likewise, findings
Table 1 American Academy of Neurology evidence classification
scheme for determining the yield of established diagnostic and
screening tests
Class I: A statistical,1 population-based2 sample of patients
studied at a uniform point in time (usually early) during the
course of the condition. All patients undergo the intervention
of interest. The outcome, if not objective,5 is determined in an
evaluation that is masked to the patients’ clinical
presentations.
Class II: A statistical, non-referral-clinic-based3 sample of
patients studied at a uniform point in time (usually early)
during the course of the condition. Most (80%) patients
undergo the intervention of interest. The outcome, if not
objective,5 is determined in an evaluation that is masked to
the patients’ clinical presentations.
Class III: A selected, referral-clinic-based4 sample of patients
studied during the course of the condition. Some patients
undergo the intervention of interest. The outcome, if not
objective,5 is determined in an evaluation by someone other
than the treating physician.
Class IV: Expert opinion, case reports, or any study not meeting
criteria for class I to III.
This is a new classification scheme developed by the Quality
Standards Subcommittee (QSS) for studies related to determin-
ing the yield of established diagnostic and screening tests or in-
terventions and is appropriate only when the diagnostic accuracy
of the test or intervention is known to be good. Additionally, the
abnormality potentially identified by the screening intervention
should be treatable or should have important prognostic implica-
tions. This classification is different from others currently recom-
mended by the QSS that have been published in recent
parameters that relate to diagnostic, prognostic, or therapeutic
studies.
1 Statistical sample: A complete (consecutive), random, or sys-
tematic (e.g., every third patient) sample of the available popu-
lation with the disease;
2 Population-based: The available population for the study con-
sists of all patients within a defined geographic region;
3 Non-referral-clinic-based: The available population for the
study consists of all patients presenting to a primary care set-
ting with the condition;
4 Referral-clinic-based: The available population for the study
consists of all patients referred to a tertiary care or specialty
setting. These patients may have been selected for more severe
or unusual forms of the condition and thus may be less repre-
sentative;
5 Objective: An outcome measure that is very unlikely to be af-
fected by an observer’s expectations (e.g., determination of
death, the presence of a mass on head CT, serum B12 assays).
Table 2 American Academy of Neurology system for translation
of evidence to recommendations
Rating of recommendations
Translation of evidence to
recommendations
A  Established as
useful/predictive or not
useful/predictive for the
given condition in the
specified population
Level A rating requires at
least one convincing class I
study or at least two
consistent, convincing class
II studies
B  Probably useful/predictive
or not useful/predictive for
the given condition in the
specified population
Level B rating requires at
least one convincing class II
study or overwhelming class
III evidence
C  Possibly useful/predictive
or not useful/predictive for
the given condition in the
specified population
Level C rating requires at
least two convincing class III
studies
U  Data inadequate or
conflicting. Given current
knowledge, test, predictor is
unproven.
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on physical examination (e.g., cataracts, chorioretini-
tis, dysmorphic features, myoclonus, dystonia) may
suggest a specific etiology or an alternative diagno-
sis. An abnormality on MRI does not necessarily
mean that the etiology of the motor deficit has been
established. For example, the findings of diffuse cor-
tical atrophy, delayed myelination, or polymicrogyria
are nonspecific and only suggest that a CNS distur-
bance was present and may not allow one to know
the underlying cause without a more specific
workup.
CT. Data from 782 children with CP who had CT
scans found abnormalities in 77% (range 62% to
93%) (see table 3a). For the class I studies (n  140),
86% of children had abnormal scans whereas 78% of
patients in class III studies (n  642) had abnormal
scans (there were no class II studies). The yield from
CT scans varied depending on the type of CP (hemi-
plegic  ataxic  mixed  diplegic  quadriplegic 
hypotonic  dyskinetic) with the percent abnormal
in those with dyskinetic CP being much lower than
in other forms of CP (table 3b).
Table 3 CT in children with cerebral palsy (CP)
a. Overall yield of finding an abnormal CT scan in children with CP
Reference Class N Ages, y Type of CP % Abnormal
Wiklund et al., 19916 I 83 5–16 H 73
Wiklund et al., 19917 I 28 5–16 H 75
Miller and Cala, 19898 I 29 6–35 A 62
Chen, 19819 III 281 0.08–7 M 84
Kolawole et al., 198910 III 120 1–10 M 73
Taudorf et al., 198411 III 83 NA M 67
Schouman-Claeys et al., 198912 III 76 0.6–15 M 63
Cohen and Duffner, 198113 III 52 0.67–10 H 87
Molteni et al., 198714 III 30 5–16 H 93
Total no. of patients 782
Mean abnormal CT 77
b. Percent of patients with an abnormal CT scan based on the type of CP (n  485)
Hemiplegic (n  146) 89 Quadriplegic (n  111) 70
Ataxic (n  19) 88 Hypotonic (n  19) 73
Mixed (n  29) 79 Dyskinetic (n  14) 36
Diplegic (n  153) 75
c. Classification of timing of injury of CP based on CT scan abnormalities (n  626)*
Reference Class N Type of CP % Prenatal % Perinatal % Postnatal % Unclassifiable
Wiklund et al., 19916 I 83 H 44 39 0 17
Wiklund et al., 19917 I 28 H 64 82 0 7
Chen, 19819 III 282 M 33 54 13 0
Kolawole et al., 198910 III 120 M 16 35 26 28
Taudorf et al., 198411 III 83 M 11 74 15 0
Molteni et al., 198714 III 30 H 53 47 0 0
Total 626
Mean values 32 50 12 6
d. Percent of patients with other etiologies of CP based on CT and clinical data (n  702)*
Metabolic 4 Brain malformation 7
Genetic 2 Treatable condition 5
* Etiologies could not be determined in all patients in the studies listed in section a and in some patients more than one category of
etiology was given. Data from the studies listed in section a.
H  hemiplegic; A  ataxic; M  mixed.
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When abnormal, CT scans are helpful in delineat-
ing the timing of the etiology of CP in most children
(table 3c). For the class I studies (n  111), onset
was prenatal in 44%, perinatal in 43%, and postnatal
in 0%. For the class III studies (n  515), onset was
prenatal in 29%, perinatal in 52%, and postnatal in
15%. In the remaining patients, the timing of the
insult was not determined. Some of the more com-
mon etiologies of prenatal onset include intrauterine
infection, stroke, toxemia, and placental abruption;
of perinatal onset, etiologies include hypoxic ische-
mic encephalopathy, kernicterus, and trauma; and of
postnatal onset, etiologies include infection, trauma,
and progressive hydrocephalus. There was insuffi-
cient information from the CT studies to calculate an
accurate breakdown by specific etiology for any of
the three groups although in many of the individual
cases a specific etiology was assigned. Etiologies tend
to be different in term and preterm babies and are
discussed further in the section on MRI.
A CT scan in a child with CP may on occasion
detect conditions that are surgically treatable that
Table 4 MRI in children with cerebral palsy (CP)
a. Overall yield of finding an abnormal MRI scan in children with CP
Reference Class N Ages, y Type of CP % Abnormal
Krageloh-Mann et al., 199515 I 56 5–17 SQ 91
Yin et al., 200016 I 42 0.25–18 M 91
Candy et al., 199317 II 22 0.25–2.25 M 77
Okumara et al., 1997, pt 218 III 152 1–19 M 78
Cioni et al., 199919 III 91 1–18.3 M 100
Jaw et al., 199820 III 86 0.33–13 M 95
Sugimoto et al., 199521 III 70 0.75–15 M 100
Hayakawa et al., 199622 III 63 0.5–6 SD 79
Truwit et al., 199223 III 40 0.08–41 M 93
Yokochi et al., 199124 III 22 NA D 68
Total no. of patients 644
Mean abnormal MRI 89
b. Percent of patients with an abnormal MRI scan based on the type of CP (n  286)
Mixed (n  4) 100 Ataxic (n  8) 75
Quadriplegic (n  105) 98 Dyskinetic (n  10) 70
Hemiplegic (n  50) 96 Hypotonic (n  6) 67
Diplegic (n  102) 94
c. Classification of timing of injury of CP based on MRI scan abnormalities*
Reference Class N Type of CP % Prenatal % Perinatal % Postnatal % Unclassifiable
Krageloh-Mann et al., 199515 I 56 SQ 14 39 0 46
Yin et al., 200016 I 42 M 26 54 3 18
Cioni et al., 199919 III 91 M 59 30 11 0
Jaw et al., 199820 III 86 M 29 28 3 8
Sugimoto et al., 199521 III 70 M 44 37 0 19
Total 345
Mean values 37 35 4 15
d. Percent of patients with other etiologies of CP based on MRI and clinical data (n  682)*
Metabolic 0 Brain malformation 12
Genetic 1.4 Treatable condition 0.1
* Etiologies could not be determined in all patients in the studies listed in section a and in some patients more than one category of
etiology was given. In some studies there were no data provided as to a specific etiology.
SQ  spastic quadriplegic; M  mixed; SD  spastic diplegic; NA  not available; D  dyskinetic.
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might not be detected by neurologic examination.
The chance of finding a surgically treatable lesion
based on data from 702 children with various types
of CP is 5% (range 0% to 22.5%) (table 3d). This may
vary as one class III study reported that 22.5% of
120 patients had potentially treatable lesions identi-
fied (hydrocephalus, porencephaly, arteriovenous
malformation, subdural hematomas and hygromas,
and a vermian tumor).10 The majority of other stud-
ies reported either no patients with potentially treat-
able lesions6,13,14 or lower incidences of 5%,9 14%,11
and 17%.8 On occasion, CT (as well as MRI) may
detect abnormalities that suggest a potentially treat-
able inborn error of metabolism.
When the CT scan is abnormal, the presence of
coexisting conditions should be anticipated. In stud-
ies of 240 children with CP, the presence of mental
retardation was greater if scans were abnormal than
if they were normal or had minor abnormalities (78%
versus 39%).8,11-13 Three of these studies had addi-
tional data regarding the relation between CT find-
ings and epilepsy.8,11,12 Ninety-one percent of children
with CP who had an abnormal CT scan had epilepsy
or an abnormal EEG in contrast to only 38% of chil-
dren whose scans were normal or minimally abnor-
mal. One of these studies found normal EEG in 37%,
paroxysmal EEG in 44%, and other abnormalities
such as hemispheric asymmetry or suppression of
activity in 19% of children.13 Although an abnormal
CT suggested greater risk of coexistent conditions,
the specific nature of these conditions (e.g., type of
epilepsy) did not correlate with scan abnormalities.13
Conclusions. Data from three class I (75%) and
six class III (77%) studies indicate that the yield of
finding an abnormal CT scan in a child with CP is
high (average of 77%) and related to the type of CP.
Scan abnormalities may determine an etiology in
many children but there were insufficient data to
assess this further. Scan abnormalities may occa-
sionally (i.e., 5 to 22%) identify treatable conditions
and may suggest an increased risk for associated
conditions such as mental retardation and epilepsy.
MRI. Data from studies involving 644 children
with CP who had MRI scans found abnormalities in
Table 5 MRI abnormalities in children with cerebral palsy based on preterm, term, and postnatal onset of insult
Abnormalities Preterm (n  335) Term (n  272) Postnatal (n  29)
Acquired lesions 261 178 22
PVL with other areas of injury 227 45 —
Diffuse encephalopathy (cortical/subcortical atrophy/
ventriculomegaly)
14 71 —
Focal ischemic/hemorrhagic (e.g., infarct porencephaly) 14 52 10
Multicystic encephalomalacia 3 10 —
Trauma (at birth or later) 0 0 4
Infection 3 0 8
Malformations* 48 55 0
Cortical dysplasia/polymicrogyria 8 18 —
Schizencephaly 6 11 —
Pachygyria/lissencephaly 5 9 —
Complex brain malformation 22 6 0
Agenesis/hypoplasia of the corpus callosum 3 3 —
Arachnoid cyst 1 0 —
Vermian/cerebellar hypoplasia 1 2 —
Hydrocephalus/holoprosencephaly/hydranencephaly 2 2 —
Miscellaneous/unknown 23 18 1
Miscellaneous etiologies 22 9 1
Delayed/abnormal myelination 1 9 0
Normal 3 21 6
Data from the following studies: Yin et al., 200016; Okumara et al., 1997, pt 218; Cioni et al., 199919; Sugimoto et al., 199521; Hayakawa
et al., 199622; Krageloh-Mann et al., 199515; Yokochi et al., 199124; Candy et al., 199317; Jaw et al., 199820; Truwit et al., 1992.23 Abnor-
malities considered insults on neuroimaging were designated as preterm (insult occurred before 38 weeks gestation whether infant
born prematurely or at term), term (insult occurred after full term gestation in the perinatal period up to 1 month of age), or postnatal
(insult occurred after 1 month of age in infants born prematurely or at term). Malformations were categorized as preterm if detected in
infants born before 38 weeks gestation or term if detected in infants born after a full term pregnancy.
* The data in the malformations section of this table are separated into preterm, term, and post-term as that is how they were reported
in the original reports. It is believed, however, that these malformations occur prenatally.
PVL  periventricular leukomalacia.
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89% (range 68% to 100%) (see table 4a). For the two
class I studies (n  98), 92% of children had abnor-
mal scans whereas 77% of patients in one class II
study (n  22) had abnormal scans as did 89% of
children in the class III studies (n  524). The yield
on MRI (table 4b) depended on the type of CP that
was present (mixed  quadriplegic  hemiplegic 
diplegic  ataxic  dyskinetic  hypotonic) and was
somewhat different from that reported using CT.
MRI was helpful in determining whether the in-
jury was prenatal, perinatal, or postnatal in onset
(table 4c). Based on studies involving 345 children
(class I n  98; class III n  247) with different types
of CP, onset was prenatal in 37% (29% in class I and
45% in class III studies), perinatal in 35% (45% in
class I and 31% in class III), and postnatal in 4% (1%
in class I and 5% in class III studies). The yield from
MRI also depended on whether the child with CP
was born prematurely, at term, or whether CP was
due to an insult later in life. Data from studies on
620 patients found that MRI scans were abnormal in
332/335 (99%) preterm infants, 251/272 (92%) term
infants, and 23/29 (79%) infants older than 1 month
(table 5). In most series, this was due to the fact that
MRI was more sensitive in detecting periventricular
leukomalacia, other perinatally acquired lesions, as
well as subtle congenital anomalies of brain develop-
ment. MRI can help define abnormalities based on
the timing of insult in most patients as summarized
in table 5. The etiology of CP in these children was
suggested or established based on neuroimaging
findings in combination with the clinical history.
Conclusions. Data from two class I (92%), one
class II (77%), and seven class III studies (89%) indi-
cate that the yield of finding an abnormal MRI scan
in a child with CP is very high (average of 89%) and
greater than that reported using CT (77%). The yield
on MRI (as with CT) depends on the type of CP that
is present. MRI is more likely to be abnormal in
cases of CP associated with prematurity, showing
abnormalities such as periventricular leukomalacia,
compared to infants born at term. An etiology of CP
can be determined in many patients based on the
results of neuroimaging in combination with the clin-
ical history.
Recommendations. 1. Neuroimaging is recom-
mended in the evaluation of a child with CP if the
etiology has not been established; for example, by
perinatal imaging (Level A, class I and II evidence).
2. MRI, when available, is preferred to CT scan-
ning because of the higher yield of suggesting an
etiology and timing of insult leading to CP (Level A,
class I–III evidence).
Metabolic and genetic testing. Should metabolic
or genetic testing be routinely ordered in children
with CP?
Evidence. Data from 2 class I, 13 class II, and 4
class III studies on 1,384 children with CP who un-
derwent neuroimaging (CT or MRI) and who also
had metabolic and genetic testing indicate that it is
rare to identify an underlying metabolic or genetic
disorder. The mean incidence of metabolic (4%) and
genetic disorders (2%) in those children who had CT
scans was slightly higher than with MRI (metabolic,
0%; genetic, 1.4%) and did not vary substantially
between the different classes of studies (see tables 3d
and 4d). The low and variable incidence of metabolic
and genetic disorders in these studies was, in part,
due to patient selection factors, as in some studies
children with metabolic disorders were excluded
from analysis.17 Also, in these retrospective studies,
the extent and type of metabolic or genetic testing
was variable so that the exact prevalence of such
disorders in children with CP remains uncertain.
Since the advent of neuroimaging, it has become
more apparent that children with CP may have con-
genital brain malformations. Data from this same
group of 1,426 children found that 7% of patients
who had a CT scan and 12% of those who underwent
MRI had major brain malformations such as lissen-
cephaly, schizencephaly, or pachygyria (see tables 3d
and 4d). Because these malformations are ever in-
creasingly associated with specific genetic disorders
(e.g., lissencephaly/Miller-Dieker syndrome/chromo-
some 17p13.3), their presence in affected children
indicates the need for further genetic testing. Cer-
tain neurometabolic disorders (e.g., peroxisomal dis-
orders such as Zellweger syndrome) may be
associated with cerebral malformations and can
present within the first years of life with a motor
deficit that might appear to be nonprogressive. At
present, no studies have prospectively evaluated
children with CP with or without brain malforma-
tions to determine the incidence of metabolic or ge-
netic abnormalities.
Metabolic disorders may on rare occasions mas-
querade as CP. Six small case series (i.e., class IV
studies) describe 30 children who ultimately devel-
oped what appeared to be dyskinetic CP due to glu-
taric aciduria (type 1).25-30 These children typically
develop normally until 5 to 10 months of age when
they suffer an acute encephalopathy manifested by
coma that is followed by dystonia, motor impairment,
and macrocephaly (in about 60%).25 Distinctive MRI
and CT findings occur in half the patients and are
manifested by frontal and temporal atrophy. Early di-
agnosis is important as glutaric aciduria is treatable;
early intervention may prevent significant motor and
cognitive impairment.28 Other metabolic disorders pre-
senting with symptoms suggestive of CP also have
been reported in small case series and include Lesch-
Nyhan syndrome,31 3-methylglutaconic aciduria,32
pyruvate dehydrogenase deficiency,33 argininemia,34 cy-
tochrome oxidase deficiency,35 succinic semialdehyde
dehydrogenase deficiency,36 and female carriers of orni-
thine transcarbamylase deficiency.37
Other childhood neurologic disorders (e.g., dopa-
responsive dystonia, hereditary spastic paraplegia,
ataxia telangiectasia) may initially be misdiagnosed
as CP because of the slow rate of progression of
symptoms. Other clinical or laboratory features of
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such conditions and observations over time that neu-
rologic symptoms are progressive should suggest
that the child does not have CP and mandates the
need for further evaluation.
Conclusions. Metabolic or genetic causes for CP
occur infrequently (i.e., 0 to 4%). However, the true
incidence is unknown as there have been no prospec-
tive studies that have examined this issue. In almost
all such cases, there are atypical complaints, fea-
tures in the history of a progressive rather than a
static encephalopathy, findings on neuroimaging
that are representative of certain genetic or meta-
bolic disorders, or a family history of childhood neu-
rologic disorder with associated CP. Neuroimaging
studies have shown that 7 to 11% of children with
CP will have a brain malformation suggesting addi-
tional risk for genetic and possibly a metabolic
etiology.
Recommendations. 1. Metabolic and genetic
studies should not be routinely obtained in the eval-
uation of the child with CP (Level B, class II and III
evidence).
2. If the clinical history or findings on neuroimag-
ing do not determine a specific structural abnormal-
ity or if there are additional and atypical features in
the history or clinical examination, metabolic and
genetic testing should be considered (Level C, class
III and IV).
3. Detection of a brain malformation in a child
with CP warrants consideration of an underlying ge-
netic or metabolic etiology (Level C, class III and IV
evidence).
Coagulopathies. Should coagulation studies be
performed in children with CP?
Evidence. Patients with hemiplegic CP fre-
quently have suffered a prenatal or perinatal cere-
bral infarction. Data from three CT studies listed in
table 3a (n  196) found cerebrovascular occlusion,
usually in the middle cerebral artery distribution, in
13%,6 32%,11 and 37%14 of individuals. There are in-
sufficient data concerning the incidence of cerebral
infarction or other causes of cerebrovascular compro-
mise in children with other forms of CP.
Children, in contrast to adults, often have a co-
agulopathy, congenital heart disease, or an infec-
tious process as the etiology of stroke.38 However,
none of the MRI series listed in table 4a focused on
children with hemiplegic CP. None of the reported
series (see tables 3 and 4) included information indi-
cating that a systematic examination for the etiology
of infarction was performed. One class I study39 and
several class II studies have reported coagulation
abnormalities as the etiology of neonatal cerebral
infarction.39-42 These have included Factor V Leiden
deficiency, the presence of anticardiolipin or an-
tiphospholipid antibodies, and Protein C or S defi-
ciency. One class III study42 and several class IV case
reports43-46 have also described the relation between
neonatal cerebral infarction, coagulopathies, and a
later diagnosis of hemiplegic CP.
Conclusions. Class I–III evidence indicates that
cerebral infarction due to pre- or perinatal cerebro-
vascular occlusion occurs in 13 to 37% of children
with hemiplegic CP. Class II and III evidence sug-
gests that an etiology of cerebral infarction in this
population may be due to a coagulation disorder and
that the yield of testing will be higher if done in the
neonatal period rather than if the child is evaluated
later at the time of diagnosis of CP. There is insuffi-
cient evidence regarding the relation between coagu-
lation disorders and other forms of CP.
Recommendations. Because the incidence of un-
explained cerebral infarction seen with neuroimag-
ing is high in children with hemiplegic CP,
diagnostic testing for a coagulation disorder should
be considered (Level B, class II–III evidence). There
is insufficient evidence to be precise as to what stud-
ies should be ordered.
Associated conditions. What evaluations for as-
sociated conditions should be performed in children
with CP?
Evidence. Children with CP often have associ-
ated conditions such as mental retardation or epi-
lepsy that are equal in severity to their motor
impairment. Because of the motor difficulties associ-
ated with CP, these conditions may not be readily
recognized. These conditions may also seriously
hamper the ability of a child to realize his or her
intrinsic developmental potential.
Data from three class I and one class II studies
involving 886 children with CP summarize the fre-
quency of some of the major associated conditions that
occur in children with CP (table 6).47-49 The incidence of
mental retardation (52%), epilepsy (45%), ophthalmo-










Zafeiriou et al., 199947 I 493 40 39 54 15
Murphy et al., 199348 I 204 65 10 NA 4
von Wendt et al., 198549 I 69 70 19 NA 7
Kolawole et al., 198910 III 120 66 15 59 14
Total 886 52 28 38 12
NA  not available.
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logic defects (28%), speech and language disorders
(38%), and hearing impairment (12%) are quite signifi-
cant. Data from some of these studies also suggest that
those children who have abnormal neuroimaging are
more likely to have one or more of these deficits and in
some of the studies severity of scan findings was asso-
ciated with the severity of deficit.
Epilepsy. Should EEG be routinely performed in
the assessment of children with CP?
Evidence. Given the higher frequency of epilepsy
in children with CP, EEG is often considered during
the initial evaluation.47 The utility of EEG from a
diagnostic perspective in this population has not
been prospectively investigated. The vast majority of
articles on EEG and CP are class III and IV studies
that describe the frequency and types of seizures in
children with different forms of CP but do not ad-
dress the role of EEG in determining the etiology of
CP nor in predicting the development of seizures in a
child with CP.
Data from studies involving 1,918 children have
found on average that 43% (range 35 to 62%) of chil-
dren with CP develop epilepsy (table 7). In the three
class I studies (n  302), 48% had epilepsy in con-
trast to 42% of the children in the eight class II
studies (n  1,407) and 43% in the class III studies
(n  209). In none of these studies was there evi-
dence that the EEG was useful in determining the
etiology of the child’s CP.
Data from one class II study compared patients
with CP and epilepsy to those with epilepsy alone.55
Children with CP had a higher incidence of epilepsy
with onset within the first year of age (47% versus
10%), history of neonatal seizures (19% versus 3%),
status epilepticus (16% versus 1.7%), need for poly-
therapy (25% versus 3%), and treatment with
second-line antiepileptic drugs (31% versus 6.7%).
They also had a lower incidence of generalized sei-
zures (28% versus 59%) and of remaining seizure
free (37% versus 90%).55 Factors associated with a
seizure-free period of 1 year or more in epileptic chil-
dren with CP include normal intelligence, single sei-
zure type, monotherapy, and spastic diplegia.
Similar findings have been observed by other inves-
tigators in the studies listed in table 7 and are sum-
marized in the review by Wallace.47 Children with
CP who have abnormal neuroimaging studies are
more likely to have epilepsy. One class I and two
class II CT studies have examined the association
between CT findings and epilepsy.8,11,13 Fifty-four
percent of children with CP and an abnormal CT had
epilepsy in contrast to only 27% of those who had a
normal scan. In one study, EEG abnormalities (de-
scribed as paroxysmal or asymmetric) were also
much more commonly found in those children with
an abnormal CT scan.13
The prevalence of epilepsy also varies depending
on the type of CP that is present. Data from the
studies listed in table 7 indicate that children with
spastic quadriplegia (50 to 94%) or hemiplegia (30%)
have a higher incidence of epilepsy than patients
with diplegia or ataxic CP (16 to 27%). In patients
with dyskinetic CP, it may occasionally be difficult to
differentiate partial complex seizures from dyski-
netic movements.
Conclusions. Although approximately 45% of
children with CP develop epilepsy, in none of the
retrospective studies involving 2,014 children was
there evidence that the EEG was useful in determin-
ing the etiology of the child’s CP. There is no evi-
dence to make any recommendation regarding the
child with CP who does not have a history of seizures
as to whether an EEG should be ordered to screen
for epileptiform abnormalities.
Table 7 Prevalence of epilepsy in children with cerebral palsy
Reference Class N Types of cerebral palsy % Patients with epilepsy
Murphy et al., 199348 I 204 M 46
von Wendt et al., 198549 I 69 M 48
Miller and Cala, 19898 I 29 A 59
Zafeiriou et al., 199950 II 493 M 36
Hadjipanayis et al., 199751 II 323 M 42
Al-Sulaiman, 200152 II 151 M 54
Chambers et al., 199953 II 114 M 36
Bruck et al., 200154 II 100 M 62
Cioni et al., 199919 II 91 M 35
Kwong et al., 199855 II 85 M 38
Kaushik et al., 199756 II 50 M 56
Taudorf et al., 198411 III 83 M 35
Senbil et al., 200257 III 74 M 42
Cohen and Duffner, 198113 III 52 H 58
Total 1918 43
M  mixed; A  ataxic; H  hemiplegic.
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Recommendations. 1. An EEG should not be ob-
tained for the purpose of determining the etiology of
CP (Level A; class I and II evidence).
2. An EEG should be obtained when a child with
CP has a history or examination features suggesting
the presence of epilepsy or an epileptic syndrome
(Level A; class I and II evidence).
Mental retardation. Cognitive and neuropsycho-
logical function in children with CP are commonly
impaired.58 In general, there is some but no absolute
relation between the type of CP and severity of cog-
nitive impairment. Children with spastic quadriple-
gia have greater degrees of mental impairment than
children with spastic hemiplegia. Motor deficits of
children with spastic CP appear to correlate with the
severity of cognitive deficits in contrast to those chil-
dren with dyskinetic CP where this relation is
lacking.58
Children with different forms of CP may be diffi-
cult to assess because of the motor deficits and in
some forms of CP (e.g., spastic diplegia) the differ-
ences between performance and verbal intelligence
test scores actually increase with age.59 Laterality of
hemiplegia may also be a contributing factor—those
children with right hemiplegia may be more likely to
have impaired language function due to left hemi-
sphere injury,59 although this remains controver-
sial.60 There is also a strong association between
greater intellectual impairment in children with CP
and the presence of epilepsy, an abnormal EEG, or
an abnormal neuroimaging study.47
Ophthalmologic impairments. Visual impair-
ments and disorders of ocular motility are common
(28%) in children with CP (see table 6). There is an
increased presence of strabismus, amblyopia, nystag-
mus, optic atrophy, and refractive errors.61 Children
whose CP is due to periventricular leukomalacia are
also more likely to have visual perceptual problems.
Many of these difficulties should be detected if cur-
rently accepted guidelines for vision screening in
children with CP are employed.62,63
Speech and language disorders. Because of bilat-
eral corticobulbar dysfunction in many CP syn-
dromes, anarthric or dysarthric speech and other
impairments related to oral-motor dysfunction are
common. For example, articulation disorders and im-
paired speech intelligibility are present in 38% of
children with CP (see table 6).64,65 Because their im-
paired mobility can cause limited interaction with
individuals in the environment, children with CP
might not be able to develop the linguistic skills nec-
essary to develop more complex speech patterns.66
Language (as opposed to speech) deficits in CP go
hand in hand with verbal intellectual limitations as-
sociated with mental retardation.67 Oral-motor prob-
lems including feeding difficulties,68-70 swallowing
dysfunction,65,70 and drooling71 may lead to potential
serious impacts on nutrition and growth,72 oral
health,73,74 respiration,75 and self-esteem.
Hearing impairment. Hearing impairment occurs
in approximately 12% of children with CP (see table 6).
This occurs more commonly if the etiology of CP is
related to very low birth weight, kernicterus, neonatal
meningitis, or severe hypoxic-ischemic insults. Chil-
dren with CP who have mental retardation or abnor-
mal neuroimaging studies are at greater risk for
hearing impairment. Of concern are recent studies
from the Centers for Disease Control that almost half
the children found to have severe congenital hearing
loss (with or without CP) in the greater Atlanta area
were not recognized until almost age 3 years.76 Estab-
lished guidelines for neonatal audiometric screening
have recently been published.77
Conclusions. Children with CP are more likely to
have associated conditions including mental retarda-
tion (52%), ophthalmologic defects (28%), hearing im-
pairment (12%), and speech and language disorders
(38%) and additional oral-motor deficits. Children
with CP are also at greater risk for epilepsy (mean
43%; range 34 to 94%). However, there is no evidence
that an EEG is helpful in determining the etiology
of CP.
Recommendations. Because of the high incidence
of associated conditions, children with CP should be
screened for mental retardation, ophthalmologic and
hearing impairments, and speech and language disor-
ders (Level A, class I and II evidence). Nutrition,
growth, and other aspects of swallowing dysfunction
should be monitored. Further specific evaluations are
warranted if screening suggests areas of impairment.
Recommendations for the evaluation of chil-
dren with CP. Although there is insufficient evi-
dence to recommend the optimal sequence of tests to
determine the etiology of CP, taking into account
diagnostic yield and potential treatability, we pro-
pose the following consensus-based evaluation as
outlined in the algorithm (figure). All children
should undergo a detailed history and physical ex-
amination. It is important to determine that the
child’s condition is due to a static and not a progres-
sive or degenerative neurologic disorder. It is also
important to classify the type of CP as this has diag-
nostic implications as well as implications regarding
associated problems. Because children with CP com-
monly have associated mental retardation, ophthal-
mologic abnormalities, hearing impairments, speech
and language disorders, and disorders of oral-motor
function, screening for these conditions should be
part of the initial assessment. An EEG is recom-
mended when there are features suggestive of epi-
lepsy or a specific epileptic syndrome. In order to
establish an etiology and prognosis in children with
CP, neuroimaging is recommended, with MRI pre-
ferred to CT. However, if neuroimaging performed in
the perinatal period provided an etiology of the
child’s CP, it may obviate the need for later study.
Metabolic and genetic studies should not be rou-
tinely obtained in the evaluation of the child with
CP. If the clinical history or findings on neuroimag-
ing do not determine a specific structural abnormal-
ity or if there are additional and atypical features in
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the history or clinical examination, metabolic and
genetic testing should be considered. Because the
incidence of cerebral infarction is high in children
with hemiplegic CP, diagnostic testing for a coagula-
tion disorder should be considered.
Future research. 1. Prospective studies on the
etiologic yields of genetic, metabolic, and neuroimag-
ing diagnostic tests should be undertaken in large
numbers of young children with CP compared with
control subjects. This would permit the development
of specific diagnostic algorithms.
2. Large prospective cohorts of children with CP
should be studied to identify features based on CP
subtypes that can improve specific evaluation strate-
gies and enhance etiologic yield.
3. It should be determined at what age and on what
basis we can be certain that a child has CP sufficient to
justify testing and at what age the yield will be opti-
mal. Strategies of conducting testing simultaneously or
sequentially need to be assessed. This should reduce
unnecessary testing and provide cost-effective evalua-
tions (i.e., a favorable balance between the cost of test-
ing versus savings from early intervention, prevention
of the birth of affected children).
4. Studies are needed to better characterize
speech and language, ophthalmologic, auditory, oral-
motor, nutrition, and growth deficits in children with
Figure. Algorithm for the evaluation of
the child with cerebral palsy (CP).
Screening for associated conditions
(mental retardation, vision/hearing im-
pairments, speech and language delays,
oral motor dysfunction, and epilepsy) is
recommended. Neuroimaging (MRI pre-
ferred to CT) is recommended for fur-
ther evaluation if the etiology of the
child’s CP has not been previously de-
termined. In some children, additional
metabolic or genetic testing may be
indicated.
March (2 of 2) 2004 NEUROLOGY 62 861
CP. Investigation of the sensorimotor impairments of
children with CP is also needed so that studies of
early intervention therapies might be done to im-
prove the overall function of children who are likely
to have multiple needs.
5. Issues related to quality of life and social support
for families need further study. Included should be the
benefits that medical testing confers by reducing pa-
rental concerns related to determining an etiology and
by providing important information regarding progno-
sis, genetic counseling, and planning future educa-
tional and treatment needs.
6. Future research should also be directed to de-
termine the underlying mechanisms causing CP that
are associated with perinatal stroke, coagulopathies,
genetic disorders, pre- and perinatal inflammatory
diseases, and environmental factors.
Mission statement. The Quality Standards Sub-
committee (QSS) of the AAN seeks to develop scientifi-
cally sound, clinically relevant practice parameters for
the practice of neurology. Practice parameters are
strategies for patient management that assist physi-
cians in clinical decision making. A practice parame-
ter is one or more specific recommendations based on
analysis of evidence of a specific clinical problem.
These might include diagnosis, symptoms, treat-
ment, or procedure evaluation.
Disclaimer. This statement is provided as an edu-
cational service of the American Academy of Neurol-
ogy and the Child Neurology Society. It is based on
an assessment of current scientific and clinical infor-
mation. It is not intended to include all possible
proper methods of care for a particular neurologic
problem or all legitimate criteria for choosing to use
a specific procedure. Neither is it intended to exclude
any reasonable alternative methodologies. The AAN
and the CNS recognize that specific patient care de-
cisions are the prerogative of the patient and the
physician caring for the patient, based on all of the
circumstances involved.
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